Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
Science Immunology · 28.03.2025 · 10 (105)
DOI: 10.1126/sciimmunol.abo5570 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Immunology, erschienen am 28.03.2025. Verfasst von Shogo Kumagai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Neoplasms, Immune Tolerance. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 198 Literaturangaben.
Abstract (Originalsprache)
The process of tumor development involves tumor cells eluding detection and suppression of immune responses, which can cause decreased tumor cell antigenicity, expression of immunosuppressive molecules, and immunosuppressive cell recruitment to the tumor microenvironment (TME). Immunologically and genomically integrated analysis (immunogenomic analysis) of patient specimens has revealed that oncogenic aberrant signaling is involved in both carcinogenesis and immune evasion. In noninflamed cancers such as epidermal growth factor receptor ( EGFR )–mutated lung cancers, genetic abnormalities in cancer cells contribute to the formation of an immunosuppressive TME by recruiting immunosuppressive cells, which cannot be fully explained by the cancer immunoediting hypothesis. This review summarizes the latest findings regarding the links between cancer genetic abnormalities and immunosuppression causing clinical resistance to immunotherapy. We propose the concepts of immunogenomic cancer evolution, in which cancer cell genomic evolution shapes the immunosuppressive TME, and immunogenomic precision medicine, in which cancer immunotherapy can be combined with molecularly targeted reagents that modulate the immunosuppressive TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo 104-0045, Japan.
- Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Chiba 277-8577, Japan.
- Division of Cellular Signaling, Research Institute, National Cancer Center, Tokyo 104-0045, Japan.
- Department of Tumor Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan.
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
- Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan.
ORCID-Profile: Shogo Kumagai, Yusaku Momoi, Hiroyoshi Nishikawa
Zitieren
APA
Kumagai, S., Momoi, Y., & Nishikawa, H. (2025). Immunogenomic cancer evolution: A framework to understand cancer immunosuppression. Science Immunology, 10(105). https://doi.org/10.1126/sciimmunol.abo5570
Vancouver
Kumagai S, Momoi Y, Nishikawa H. Immunogenomic cancer evolution: A framework to understand cancer immunosuppression. Science Immunology. 2025;10(105). doi:10.1126/sciimmunol.abo5570
BibTeX
@article{Kumagai2025,
author = {Kumagai, Shogo and Momoi, Yusaku and Nishikawa, Hiroyoshi},
title = {Immunogenomic cancer evolution: A framework to understand cancer immunosuppression},
journal = {Science Immunology},
year = {2025},
volume = {10},
number = {105},
doi = {10.1126/sciimmunol.abo5570}
}
EUVIMED